MedPath

Adhear Bone Conduction System

Not Applicable
Terminated
Conditions
Hearing Loss, Conductive
Hearing Loss, Unilateral
Interventions
Device: Adhear Bone Conduction System
Device: Bone anchored hearing aid (BAHA)
Registration Number
NCT03533686
Lead Sponsor
University of Miami
Brief Summary

The purpose of this research study is to learn about the hearing outcomes of adult and pediatric patients who are treated with or are candidates for bone conductive devices (also termed "BAHA"). Hearing outcomes will also be assessed with a second audio processor device called the Adhear System.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
66
Inclusion Criteria

Aims 1 and 2:

  • Adult English speaking patients who are experienced users of Bone Anchored Implants (BAIs) for the indication of either single sided deafness or conductive hearing loss.
  • Experienced will be defined as greater than 6 months of device use and no intermittent function of the device within 2 weeks of enrollment.
  • Subjects will be limited to those who have normal hearing by bone conduction defined as a pure tone average of 25 dBHL or better at 500, 1000, 2000, & 3000 Hz in at least one ear.

Aim 3:

  • English speaking children 5 to 17 years of age and their primary guardian who present to the clinic for treatment by BAI on a headband device for the indications of single sided deafness or conductive hearing loss.
  • Subjects will be limited to those who have no prior use of a BAI or bone conduction hearing device, normal hearing by bone conduction defined as a pure tone average of 25 dBHL or better at 500, 1000, 2000, & 3000 Hz in at least one ear. For those children where this cannot be definitively established, children will be included who display clinical signs of normal bone conduction hearing beyond a reasonable doubt and may include such evidence as (but not limited to): auditory brainstem response, speech awareness thresholds, visual reinforcement audiometry, conditioning play audiometry, CT scans, etc.)

Aim 3 a & b:

  • Pediatric bilateral or unilateral conductive hearing loss patients who are between the ages of 2 and 17 years of age
  • Pediatric participants who are currently managed by the University of Miami with a bone conduction device attached to a softband.
Read More
Exclusion Criteria

Aims 1 & 2:

  • Non-English speakers
  • Participants reporting allergies to adhesives or highly reactive skin.

Aim 3:

  • Pediatric participants who are non-English speakers.
  • Children who have previous experience with a BAI or bone conduction hearing device will not be included for study.
  • Pediatric participants reporting allergies to adhesives or highly reactive skin.

Aims 3a & 3b:

  • Pediatric participants who are non-English speakers.
  • Pediatric participants reporting allergies to adhesives or highly reactive skin.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Single-Sided Deafness Adult (Aim1) GroupAdhear Bone Conduction SystemAdult participants with single-sided deafness and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
Adhear followed by BAHA (Aim 3) GroupBone anchored hearing aid (BAHA)Pediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
BAHA followed by Adhear (Aim 3) GroupBone anchored hearing aid (BAHA)Pediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
Pediatric Unilateral Conductive Hearing Loss (Aim 3a) GroupAdhear Bone Conduction SystemPediatric participants (aged 2-17 years) and their parents with unilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system for 2 weeks (plus up to 90 days).
Adhear followed by BAHA (Aim 3) GroupAdhear Bone Conduction SystemPediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
BAHA followed by Adhear (Aim 3) GroupAdhear Bone Conduction SystemPediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
Pediatric Bilateral Conductive Hearing Loss (Aim 3b) GroupAdhear Bone Conduction SystemPediatric participants (aged 2-17 years) and their parents with bilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system. Participants who are fitted bilaterally will receive 2 Adhear systems (one for each ear) for 2 weeks (plus up to 90 days) at Visit 1. Participants who are fitted unilaterally will receive 1 Adhear system for 2 weeks (plus up to 90 days) at Visit 1, afterwards, will be fitted bilaterally at Visit 2 and receive the Adhear system for both ears for another 2 weeks (plus up to 90 days) for a total of 4 weeks (plus up to 180 days).
Conductive Hearing Loss Adult (Aim 2) GroupAdhear Bone Conduction SystemAdult participants with conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
Primary Outcome Measures
NameTimeMethod
Aided Hearing Thresholds for Conductive Hearing LossDay 14

Aided-hearing thresholds represent the softest sound that the participant can hear inside the audiometric test booth when using a hearing device. Aided hearing thresholds were measured using the participant's own device on a softband and the Adhear device in the test booth on day 14. Hearing thresholds were measured in hertz.

Aided Hearing ThresholdsDay 14 of the intervention

Aided-hearing thresholds represent the softest sound that the participant can hear inside the audiometric test booth when using a hearing device. Aided hearing thresholds were measured using a traditional bone conduction device on a softband and the Adhear device in the test booth on day 14. Hearing thresholds were measured in hertz.

Aided Hearing Thresholds for Single Sided DeafnessDay 14

Aided-hearing thresholds represent the softest sound that the participant can hear inside the audiometric test booth when using a hearing device. Aided hearing thresholds were measured using the participant's own device on a softband and the Adhear device in the test booth on day 14. Hearing thresholds were measured in hertz.

Secondary Outcome Measures
NameTimeMethod
Aided Speech in Noise Performance in Participants With Single-sided DeafnessDay 14

Aided speech-in-noise performance is the ability to identify spoken words when background noise is present while using a hearing device. Aided speech-in-noise performance was measured using the participant's own device on a softband and the Adhear device in the test booth on day 14. Aided speech-in-noise performance was measured in decibels.

Participant Satisfaction With BAHA (Aims 1, 2, 3a and 3b) or No Device (Aim 3)Day 1

Custom Subjective Device Questionnaire measured auditory, social emotional, and device satisfaction as a composite score using a Likert scale. Likert score range was 1-4. Higher scores denoted positive responses. The reported values represent an average across the multiple domains of the questionnaire.

Aided Speech-in-noise Performance in Participants With Single-sided DeafnessDay 1

Aided speech-in-noise performance is the ability to identify spoken words when background noise is present while using a hearing device. Aided speech-in-noise performance was measured using the participant's own device on their abutment and the Adhear device in the test booth on day 1. Aided speech-in-noise performance was measured in decibels.

Participant Satisfaction With AdhearDay 14

Custom Subjective Device Questionnaire measured auditory, social emotional, and device satisfaction as a composite score using a Likert scale. Likert score range was 1-4. Higher scores denoted positive responses. The reported values represent an average across the multiple domains of the questionnaire.

Participant Satisfaction With Adhear at Day 28 (Aim 3b)Day 28

Custom Subjective Device Questionnaire measured auditory, social emotional, and device satisfaction as a composite score using a Likert scale. Likert score range was 1-4. Higher scores denoted positive responses. The reported values represent an average across the multiple domains of the questionnaire.

Aided Speech in Noise Performance in Participants With Conductive Hearing LossDay 14

Aided speech-in-noise performance is the ability to identify spoken words when background noise is present while using a hearing device. Aided speech-in-noise performance was measured using the participant's own device on a softband and the Adhear device in the test booth on day 14. Aided speech-in-noise performance was measured in decibels.

Trial Locations

Locations (1)

University of Miami Department of Otolaryngology

🇺🇸

Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath